Loading…
Chinese biotech developing antiviral drugs (hepatitis, HIV) and newer obesity/metabolic and oncology drug candidates.
Chinese biotech developing antiviral drugs (hepatitis, HIV) and newer obesity/metabolic and oncology drug candidates.
Income so far is small next to development spending, which is funded by investor money and out-licensing deals. Success rests on its obesity candidates reaching late-stage trials.
Moat: narrow (IP / patents). First-mover China antiviral approvals and a differentiated oral obesity pipeline, still early-stage overall.
Headquarters: Hangzhou, China · Founded: 2013 · Employees: 202
Size Ascletis Pharma (1672.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $610M, the 711th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$4.55 on 6 Nov 2026.
Performance Over six months the shares fell 73.1%, against -14.2% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — lowest of 18 in its peer set.
Growth Revenue fell 59.4% over the last twelve months (peer median +7.7%); the operating margin is -71,976.2% (peer median -48.8%).
Valuation It trades at 2,088.7× enterprise value to sales against a peer median of 4.0× (most expensive of 15).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.04M | HK$2.20M | HK$1.39M | HK$62.5M | HK$62.9M |
| Revenue growth | — | +58% | -98% | -1% | — |
| Gross profit | -HK$18.3M | -HK$18.5M | -HK$21.7M | HK$7.97M | -HK$58.3M |
| EBITDA | -HK$727M | -HK$506M | -HK$415M | -HK$320M | -HK$365M |
| Net income | -HK$662M | -HK$390M | -HK$326M | -HK$160M | -HK$366M |
| Free cash flow | -HK$566M | -HK$368M | -HK$239M | -HK$166M | -HK$174M |
| Capital expenditure | HK$2.48M | HK$2.14M | HK$2.33M | HK$21.2M | HK$16.7M |
| Total debt | n/a | HK$5.75M | HK$8.12M | HK$9.27M | HK$4.76M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Ascletis Pharma 1672.HK | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 7.4× | 11.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 8.8× | 14.9% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1672.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -46.1% | -12.0% | lowest of 21 |
| 6-month return | -73.1% | -14.2% | lowest of 18 |
| Distance from 52-week high | -77.1% | -45.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | -59.4% | +7.7% | lowest of 15 |
| Operating margin | -71,976.2% | -48.8% | lowest of 15 |
| EV / Sales | 2,088.7× | 4.0× | most expensive of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 11.2× | 40.0% | +143.5% |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | 20.3× | n/a | n/a |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 1.6× | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | 25.7× | n/a | n/a |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | 2.0× | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | 2.7× | -8.3% | -1.3% |
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | 3.9× | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 4.1× | 35.4% | +27.2% |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $554M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $553M | -19% | +6% | -11% | 6.5× | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | 3.9× | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 4.7× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 2.1× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | 7.0× | 31.6% | +7.0% |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | 4.0× | n/a | n/a |